RWO 1L lupatercept vs 2L ESA
FACE-OFF: Low-Risk MDS ASH 2025
Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.
| WATCH NOW |
Featured Video
 RWO 1L lupatercept vs 2L ESA Explore real-world outcomes of Luspatercept and second-line ESAs in treating low-risk MDS, revealing promising response rates and treatment insights.
|